Skip to search formSkip to main contentSkip to account menu

XR9576

Known as: XR 9576 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tariquidar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.
2010
2010
Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET
ObjectiveXR9576 (tariquidar) is an anthranilic acid derivative and potent P-glycoprotein (P-gp) inhibitor. XR9576 has undergone… 
2009
2009
Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators.
Highly Cited
2009
Highly Cited
2009
A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
Purpose: P-glycoprotein (Pgp) antagonists have had unpredictable pharmacokinetic interactions requiring reductions of… 
2005
2005
The coupling mechanism of P‐glycoprotein involves residue L339 in the sixth membrane spanning segment
2005
2005
Alterations in respiration rate of isolated rainbow trout hepatocytes exposed to the P-glycoprotein substrate rhodamine 123.
Highly Cited
2003
Highly Cited
2003
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
99mTc-sestamibi, a substrate of the multidrug transporter P-glycoprotein (Pgp), has been used as a functional imaging agent for… 
Highly Cited
2003
Highly Cited
2003
Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation.
Highly Cited
2001
Highly Cited
2001
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells causes multidrug resistance (MDR). This protein acts as… 
Highly Cited
2000
Highly Cited
2000
Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.
XR9576 is a novel inhibitor of P-glycoprotein (P-gp) that has been shown to reverse P-gp-dependent multidrug-resistance in tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)